# Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)

> **NCT00688207** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 14 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Rosiglitazone (Extended Release)

## Key facts

- **NCT ID:** NCT00688207
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2016-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00688207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00688207, "Mild Alzheimer''s Disease to Assess the of Extended Release Formulation of Rosiglitazone (RSG XR)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00688207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*